"Gilead Sciences Inc. said Monday it started late stage clinical testing of its four-in-one 'Quad' HIV tablet," the Associated Press reports. The pill includes the drugs elvitegravir, cobicistat, and the two components of Truvada, emtricitabine and tenofovir (4/12). "The Phase III clinical program for the Quad includes two studies ... that will evaluate the Quad regimen versus a standard of care among" HIV-positive adults who have not yet started antiretroviral treatment, according to a Gilead press release (4/12).
This information was reprinted from kff.org with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.